Type 1 Diabetes TrialNet

A multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes

Polly J. Bingley, Diane K. Wherrett, Ann Shultz, Lisa Rafkin, Mark A. Atkinson, Carla J. Greenbaum

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery, translational, and clinical research operating in partnership with funders and industry and in sync with regulatory agencies are needed. This Perspective describes one such effort, Type 1 Diabetes TrialNet, a National Institutes of Health-funded and JDRFsupported international clinical trials network that emerged from the Diabetes Prevention Trial-Type 1 (DPT-1). Through longitudinal natural history studies, as well as trials before and after clinical onset of disease combined with mechanistic and ancillary investigations to enhance scientific understanDing and translation to clinical use, TrialNet is working to bring disease-modifying therapies to individuals with type 1 diabetes. Moreover, TrialNet uses its expertise and experience in clinical studies to increase efficiencies in the conduct of trials and to reduce the burden of participation on individuals and families. Herein, we highlight key contributions made by TrialNet toward a revised understanDing of the natural history of disease and approaches to alter disease course and outline the consortium's plans for the future.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalDiabetes Care
Volume41
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Type 1 Diabetes Mellitus
Therapeutics
Translational Medical Research
National Institutes of Health (U.S.)
Natural History
Industry
Research Personnel
Clinical Trials

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Type 1 Diabetes TrialNet : A multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes. / Bingley, Polly J.; Wherrett, Diane K.; Shultz, Ann; Rafkin, Lisa; Atkinson, Mark A.; Greenbaum, Carla J.

In: Diabetes Care, Vol. 41, No. 4, 01.04.2018, p. 653-661.

Research output: Contribution to journalReview article

Bingley, Polly J. ; Wherrett, Diane K. ; Shultz, Ann ; Rafkin, Lisa ; Atkinson, Mark A. ; Greenbaum, Carla J. / Type 1 Diabetes TrialNet : A multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes. In: Diabetes Care. 2018 ; Vol. 41, No. 4. pp. 653-661.
@article{89a0c54f2b5843dfb2d781bf378ea5e6,
title = "Type 1 Diabetes TrialNet: A multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes",
abstract = "What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery, translational, and clinical research operating in partnership with funders and industry and in sync with regulatory agencies are needed. This Perspective describes one such effort, Type 1 Diabetes TrialNet, a National Institutes of Health-funded and JDRFsupported international clinical trials network that emerged from the Diabetes Prevention Trial-Type 1 (DPT-1). Through longitudinal natural history studies, as well as trials before and after clinical onset of disease combined with mechanistic and ancillary investigations to enhance scientific understanDing and translation to clinical use, TrialNet is working to bring disease-modifying therapies to individuals with type 1 diabetes. Moreover, TrialNet uses its expertise and experience in clinical studies to increase efficiencies in the conduct of trials and to reduce the burden of participation on individuals and families. Herein, we highlight key contributions made by TrialNet toward a revised understanDing of the natural history of disease and approaches to alter disease course and outline the consortium's plans for the future.",
author = "Bingley, {Polly J.} and Wherrett, {Diane K.} and Ann Shultz and Lisa Rafkin and Atkinson, {Mark A.} and Greenbaum, {Carla J.}",
year = "2018",
month = "4",
day = "1",
doi = "10.2337/dc17-0806",
language = "English (US)",
volume = "41",
pages = "653--661",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Type 1 Diabetes TrialNet

T2 - A multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes

AU - Bingley, Polly J.

AU - Wherrett, Diane K.

AU - Shultz, Ann

AU - Rafkin, Lisa

AU - Atkinson, Mark A.

AU - Greenbaum, Carla J.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery, translational, and clinical research operating in partnership with funders and industry and in sync with regulatory agencies are needed. This Perspective describes one such effort, Type 1 Diabetes TrialNet, a National Institutes of Health-funded and JDRFsupported international clinical trials network that emerged from the Diabetes Prevention Trial-Type 1 (DPT-1). Through longitudinal natural history studies, as well as trials before and after clinical onset of disease combined with mechanistic and ancillary investigations to enhance scientific understanDing and translation to clinical use, TrialNet is working to bring disease-modifying therapies to individuals with type 1 diabetes. Moreover, TrialNet uses its expertise and experience in clinical studies to increase efficiencies in the conduct of trials and to reduce the burden of participation on individuals and families. Herein, we highlight key contributions made by TrialNet toward a revised understanDing of the natural history of disease and approaches to alter disease course and outline the consortium's plans for the future.

AB - What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery, translational, and clinical research operating in partnership with funders and industry and in sync with regulatory agencies are needed. This Perspective describes one such effort, Type 1 Diabetes TrialNet, a National Institutes of Health-funded and JDRFsupported international clinical trials network that emerged from the Diabetes Prevention Trial-Type 1 (DPT-1). Through longitudinal natural history studies, as well as trials before and after clinical onset of disease combined with mechanistic and ancillary investigations to enhance scientific understanDing and translation to clinical use, TrialNet is working to bring disease-modifying therapies to individuals with type 1 diabetes. Moreover, TrialNet uses its expertise and experience in clinical studies to increase efficiencies in the conduct of trials and to reduce the burden of participation on individuals and families. Herein, we highlight key contributions made by TrialNet toward a revised understanDing of the natural history of disease and approaches to alter disease course and outline the consortium's plans for the future.

UR - http://www.scopus.com/inward/record.url?scp=85044508612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044508612&partnerID=8YFLogxK

U2 - 10.2337/dc17-0806

DO - 10.2337/dc17-0806

M3 - Review article

VL - 41

SP - 653

EP - 661

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -